Chromocell to Present at Healthcare Company Showcase on May 21, 2024

Chromocell Corporation, headquartered in Freehold, New Jersey, has announced that its CEO, Frank Knuettel, will present at the Alliance Global Partners Healthcare Company Showcase on Tuesday, May 21, 2024. Chromocell, traded on the NYSE American under the ticker CHRO, is renowned for its pioneering work in developing non-opioid pain treatment therapeutics.

The upcoming conference, organized by Alliance Global Partners, offers a platform for leading healthcare companies to discuss significant industry catalysts and share their insights on future industry trends. The event will feature 20-minute presentations in a ‘fireside chat’ format, which will be moderated by Jim Molloy and Scott Henry from A.G.P. This format allows for an engaging and in-depth discussion, highlighting the participating companies' strategic outlook and developments.

The primary audience for this event includes investors who can attend and observe the presentations throughout the day. Those interested in the showcase can register through the A.G.P. Healthcare Showcase Registration link.

Chromocell Therapeutics Corporation is a clinical-stage biotechnology firm that focuses on creating and commercializing innovative, non-addictive treatments for pain and other related medical conditions. The company's primary clinical objective is the selective targeting of the sodium ion-channel NaV1.7. This target is crucial for treating various types of chronic neuropathic pain and both acute and chronic eye pain. Chromocell's research portfolio also extends to pre-clinical work on other sodium channel receptor subtypes, with plans to explore these compounds for additional pain indications.

The company is committed to providing updates and further information about its progress and initiatives through its website and social media channels. Chromocell's approach to pain management aims to offer effective relief without the addictive side effects associated with opioid treatments, making it a significant player in the biotechnology and pharmaceutical industry.

In summary, Chromocell's participation in the Alliance Global Partners Healthcare Company Showcase underscores its leadership in the development of non-opioid pain therapeutics. The event provides an excellent opportunity for the company to present its cutting-edge research and future plans to a broad audience, including potential investors and industry stakeholders.